• Molecular NameNateglinide
  • Synonymnateglinide; Nateglinide [INN]; SDZ-DJN 608
  • Weight317.429
  • Drugbank_IDDB00731
  • ACS_NO105816-04-4
  • Show 3D model
  • LogP (experiment)3.824
  • LogP (predicted, AB/LogP v2.0)2.54
  • pka3.1
  • LogD (pH=7, predicted)-1.02
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)-0.56
  • LogSw (predicted, AB/LogsW2.0)0.03
  • Sw (mg/ml) (predicted, ACD/Labs)0.11
  • No.of HBond Donors2
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds6
  • TPSA66.4
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA drug for the treatment of type 2 diabetes.
  • Absorption_value83.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability73.0
  • Protein binding98.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic, via cytochrome P450 isoenzymes CYP2C9 and CYP3A4. Metabolism is via hydroxylation followed by glucuronidation. The major metabolites have less antidiabetic activity than nateglinide, but the isoprene minor metabolite has antidiabetic activity comparable to that of nateglinide.
  • Half life1.5 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityAn overdose may result in an exaggerated glucose-lowering effect with the development of hypoglycemic symptoms.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A